1. Multicenter visual outcomes comparison of 2 trifocal presbyopia-correcting IOLs: 6-month postoperative results
- Author
-
Juan G. Sanchez, Chandra Bala, Wilson Takashi Hida, Ruth Lapid-Gortzak, Aldo Martinez, Uday K. Bhatt, Francisco Jose Rodriguez Alvira, Ricardo Menon Nosé, Merce Guarro, Ophthalmology, and Other Research
- Subjects
Male ,medicine.medical_specialty ,Visual acuity ,Pseudophakia ,genetic structures ,Mesopic vision ,media_common.quotation_subject ,Prosthesis Design ,Refraction, Ocular ,03 medical and health sciences ,Random Allocation ,0302 clinical medicine ,Ophthalmology ,medicine ,Postoperative results ,Contrast (vision) ,Humans ,Prospective Studies ,Dioptre ,media_common ,Aged ,Lenses, Intraocular ,Vision, Binocular ,Phacoemulsification ,business.industry ,Glare (vision) ,Presbyopia ,medicine.disease ,Sensory Systems ,eye diseases ,Patient Satisfaction ,030221 ophthalmology & optometry ,Surgery ,Female ,sense organs ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Photopic vision - Abstract
PURPOSE: To clinically evaluate visual performance of the AcrySof IQ PanOptix TFNT00 and AT LISA tri 839MP intraocular lenses (IOLs) in binocular visual acuity (VA) and to characterize low-contrast visual performance at 6 months postimplantation. SETTING: Multicenter, 15 sites. DESIGN: Prospective, parallel-group, randomized, double-masked, postmarketing clinical study. METHODS: Binocular uncorrected distance (UDVA, 4 m), intermediate (UIVA, 60 cm), and near (UNVA, 40 cm) visual acuities and binocular defocus curves were evaluated under photopic lighting conditions. Photopic and mesopic contrast sensitivities with and without glare were assessed. RESULTS: The study included 182 subjects (62% women; mean age, 66 ± 9.4 years) who were implanted bilaterally with the TFNT00 IOL (n = 93) or 839MP IOL (n = 89), and binocular VA was evaluated 4 to 6 months (120-180 days) postimplantation. The TFNT00 IOL group showed superior visual outcomes compared with the 839MP IOL group in binocular UIVA (P = .001) and UNVA (P = .003) and noninferior outcomes in UDVA (95% CI, -0.023 to 0.041; upper limit
- Published
- 2020